Vaccine Case-Population: A New Method for Vaccine Safety Surveillance.

Abstract:

INTRODUCTION:The case-population approach compares exposure among cases to that of their source population. By using aggregated data to estimate the denominator, this approach can provide a real-time estimate of an association that could be particularly valuable to explore urgent vaccine safety concerns and to generate signals during a vaccine campaign. OBJECTIVE:Our objective was to present the vaccine case-population method, a method derived from the case-population approach and adapted for vaccine safety surveillance, and to test it using several published examples. METHODS:For the vaccine case-population method, exposure in the population is estimated from the sum of at-risk periods using the number of vaccinated individuals, or data of vaccine sales, and the at-risk period considered for the vaccine-event pair. The vaccine case-population method was applied to data from published case-control studies retrieved from the MEDLINE database and having quantified risks associated with vaccines. Odds ratios derived from the vaccine case-population method were compared with those from published case-control studies. RESULTS:A total of 20 vaccine-event pairs were retrieved in which the vaccine case-population method could be applied. For all identified vaccine-event pairs, when a significant association was found using the vaccine case-population method, a significant association was also found in the corresponding case-control study. Conversely, when no association was found by the vaccine case-population method, no association was found in the corresponding case-control study. CONCLUSION:These results suggest that the vaccine case-population method can produce coherent conclusions and may be used in the future for prospective investigation of urgent vaccine safety concerns or for the prospective generation of vaccine safety signals. This method could also be used to identify selection bias from cases excluded from the case-control study.

journal_name

Drug Saf

journal_title

Drug safety

authors

Théophile H,Moore N,Robinson P,Bégaud B,Pariente A

doi

10.1007/s40264-016-0449-2

subject

Has Abstract

pub_date

2016-12-01 00:00:00

pages

1197-1209

issue

12

eissn

0114-5916

issn

1179-1942

pii

10.1007/s40264-016-0449-2

journal_volume

39

pub_type

杂志文章
  • Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003.

    abstract:BACKGROUND:Clozapine is an antipsychotic medication associated with a lower suicide rate compared with other antipsychotic agents. Clozapine is used specifically in patients for whom previous therapy was inadequate or not tolerated, and is the only antipsychotic agent associated with the development of myocarditis. OB...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200730010-00005

    authors: Haas SJ,Hill R,Krum H,Liew D,Tonkin A,Demos L,Stephan K,McNeil J

    更新日期:2007-01-01 00:00:00

  • Effects of estazolam and flurazepam on cardiopulmonary function in patients with chronic obstructive pulmonary disease.

    abstract::Benzodiazepine drugs have been shown to suppress respiratory function in patients with chronic obstructive pulmonary disease (COPD). We designed a placebo-controlled crossover study to compare the effects of a new benzodiazepine, estazolam ('ProSom'), with those of flurazepam ('Dalmane') on cardiopulmonary function in...

    journal_title:Drug safety

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00002018-199207020-00006

    authors: Cohn MA,Morris DD,Juan D

    更新日期:1992-03-01 00:00:00

  • Tolerabilities of antiretrovirals in paediatric HIV infection.

    abstract::Data on the efficacy and tolerability of antiretrovirals in children are limited as, in contrast to adult studies, large paediatric cohort studies are lacking. Thus, data pertaining to adults are often extrapolated to children despite the acknowledgement that children are not little adults. This review summarises info...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200225140-00001

    authors: Lemberg DA,Palasanthiran P,Goode M,Ziegler JB

    更新日期:2002-01-01 00:00:00

  • A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database.

    abstract:BACKGROUND:The detection of new drug safety signals is of growing importance with ever more new drugs becoming available and exposure to medicines increasing. The task of evaluating information relating to safety lies with national agencies and, for international data, with the World Health Organization Programme for I...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200023060-00004

    authors: Lindquist M,Ståhl M,Bate A,Edwards IR,Meyboom RH

    更新日期:2000-12-01 00:00:00

  • Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab.

    abstract::Eosinophils play a pivotal role in the inflammatory pathology of asthma and have been the target of new biologic treatments for patients with eosinophilic asthma. Given the central role of interleukin (IL)-5 in the eosinophil lifecycle, several therapies directed against the IL-5 pathway have been developed, including...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-020-00926-3

    authors: Jackson DJ,Korn S,Mathur SK,Barker P,Meka VG,Martin UJ,Zangrilli JG

    更新日期:2020-05-01 00:00:00

  • Spontaneous adverse drug reaction reporting in rural districts of Mozambique.

    abstract:BACKGROUND:The roll out of various public health programmes involving mass administration of medicines calls for the deployment of responsive pharmacovigilance systems to permit identification of signals of rare or even common adverse reactions. In developing countries in Africa, these systems are mostly absent and the...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200831100-00005

    authors: Sevene E,Mariano A,Mehta U,Machai M,Dodoo A,Vilardell D,Patel S,Barnes K,Carné X

    更新日期:2008-01-01 00:00:00

  • Adverse reactions to drugs as a cause of admissions to a general teaching hospital in Hong Kong.

    abstract::To determine the pattern of and the risk factors for adverse drug reactions (ADRs) in Hong Kong, a prospective study of acute admissions to 2 general medical wards at the Prince of Wales Hospital was undertaken. Of the 1701 admissions included in this study, 74 (4.4%) were attributed to ADRs. Sulphonylureas, nonsteroi...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-199207030-00008

    authors: Chan TY,Chan JC,Tomlinson B,Critchley JA

    更新日期:1992-05-01 00:00:00

  • Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.

    abstract::Pharmacovigilance science has traditionally been a discipline focussed on the postmarketing or post-authorisation period, with due attention directed towards pre-clinical safety data, clinical trials and adverse events. As the biological sciences have evolved, pharmacovigilance has slowly shifted toward earlier, proac...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200629080-00003

    authors: Hartford CG,Petchel KS,Mickail H,Perez-Gutthann S,McHale M,Grana JM,Marquez P

    更新日期:2006-01-01 00:00:00

  • Antihyperlipidaemic agents. Drug interactions of clinical significance.

    abstract::The available antihyperlipidaemic drugs are generally safe and effective, and major systemic adverse effects are uncommon. However, because of their complex mechanisms of action, careful monitoring is required to identify and correct potential drug interactions. Bile acid sequestrants are the most difficult of these a...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199411050-00002

    authors: Farmer JA,Gotto AM Jr

    更新日期:1994-11-01 00:00:00

  • Safety of thrombolysis during cardiopulmonary resuscitation.

    abstract::The prognosis is generally poor for patients who experience a cardiac arrest. The most common causes of sudden cardiac arrest are massive pulmonary embolism (PE) and acute myocardial infarction (MI). While thrombolysis is a first-line treatment option in massive PE and acute MI, cardiopulmonary resuscitation (CPR) has...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200326060-00001

    authors: Spöhr F,Böttiger BW

    更新日期:2003-01-01 00:00:00

  • Application of the bradford hill criteria to assess the causality of cisapride-induced arrhythmia: a model for assessing causal association in pharmacovigilance.

    abstract:INTRODUCTION:The Bradford Hill criteria are a widely used, useful tool for the assessment of biomedical causation. We have examined their application to pharmacovigilance using the example of cisapride-induced QTc interval prolongation/arrhythmia. METHODS:A literature search was conducted using MEDLINE, EMBASE, Reacti...

    journal_title:Drug safety

    pub_type: 杂志文章,meta分析

    doi:10.2165/00002018-200730040-00006

    authors: Perrio M,Voss S,Shakir SA

    更新日期:2007-01-01 00:00:00

  • Empirical performance of LGPS and LEOPARD: lessons for developing a risk identification and analysis system.

    abstract:BACKGROUND:The availability of large-scale observational healthcare data allows for the active monitoring of safety of drugs, but research is needed to determine which statistical methods are best suited for this task. Recently, the Longitudinal Gamma Poisson Shrinker (LGPS) and Longitudinal Evaluation of Observational...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-013-0107-x

    authors: Schuemie MJ,Madigan D,Ryan PB

    更新日期:2013-10-01 00:00:00

  • Correction to: Medication Errors: A Characterisation of Spontaneously Reported Cases in EudraVigilance.

    abstract::In the original publication of the article, the trend line for non-EEA cases in figure 4 is incorrect. In this correction, the original Fig. 4 (Fig. 1) and the correct Fig. 4 (Fig. 2) are published. ...

    journal_title:Drug safety

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40264-018-0700-0

    authors: Newbould V,Le Meur S,Goedecke T,Kurz X

    更新日期:2018-12-01 00:00:00

  • A Novel Approach to Visualize Risk Minimization Effectiveness: Peeping at the 2012 UK Proton Pump Inhibitor Label Change Using a Rapid Cycle Analysis Tool.

    abstract:INTRODUCTION:Evaluation of risk minimization (RM) actions is an emerging area of regulatory science, often without tools to rapidly and systematically assess their effectiveness. PURPOSE:The aim of this study was to evaluate whether chronographs, typically used for rapid signal detection in observational longitudinal ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-019-00853-y

    authors: Sobel RE,Blackwell W,Fram DM,Bate A

    更新日期:2019-11-01 00:00:00

  • Interest in a Mobile App for Two-Way Risk Communication: A Survey Study Among European Healthcare Professionals and Patients.

    abstract:INTRODUCTION:Previously, an app has been developed for healthcare professionals (HCPs) and patients to report adverse drug reactions (ADRs) to national medicines agencies and to receive drug safety information. OBJECTIVE:This study aimed to assess (1) European HCPs' and patients' interest in an app for this two-way ri...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-018-0648-0

    authors: de Vries ST,Denig P,Lasheras Ruiz C,Houÿez F,Wong L,Sutcliffe A,Mol PGM,IMI Web-RADR Work Package 3b Consortium.

    更新日期:2018-07-01 00:00:00

  • Current challenges and controversies in drug-induced liver injury.

    abstract::Current key challenges and controversies encountered in the identification of potentially hepatotoxic drugs and the assessment of drug-induced liver injury (DILI) are covered in this article. There is substantial debate over the classification of DILI itself, including the definition and validity of terms such as 'int...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/BF03261997

    authors: Corsini A,Ganey P,Ju C,Kaplowitz N,Pessayre D,Roth R,Watkins PB,Albassam M,Liu B,Stancic S,Suter L,Bortolini M

    更新日期:2012-12-01 00:00:00

  • A Comparative View of Reported Adverse Effects of Statins in Social Media, Regulatory Data, Drug Information Databases and Systematic Reviews.

    abstract:INTRODUCTION:There are few studies assessing how data on adverse drug events from consumers on social media compare with other sources. AIM:The aim of this study was to assess the consistency of adverse event data of statin medications from social media as compared with other sources. METHODS:We collected data on the...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-020-00998-1

    authors: Golder S,Smith K,O'Connor K,Gross R,Hennessy S,Gonzalez-Hernandez G

    更新日期:2021-02-01 00:00:00

  • Benefit-risk assessment of telithromycin in the treatment of community-acquired pneumonia.

    abstract::The purpose of this review is to assess the benefits and risks associated with the use of the ketolide antibacterial telithromycin, currently licensed for the treatment of adults with mild to moderate community-acquired pneumonia (CAP). Telithromycin is active against both the major (Streptococcus pneumoniae, Haemophi...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200831070-00002

    authors: Brown SD

    更新日期:2008-01-01 00:00:00

  • Using MedDRA: implications for risk management.

    abstract::The introduction of MedDRA, the Medical Dictionary for Regulatory Activities, as a standardised terminology may have a major impact on the performance of risk management. Thus, MedDRA is likely to have an important effect on the analysis of clinical trial safety data. Review of the most commonly used terms in clinical...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200427080-00010

    authors: Brown EG

    更新日期:2004-01-01 00:00:00

  • Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

    abstract::Epilepsy is one of the most common neurological disorders. Even though existing antiepileptic drugs can render 80% of newly diagnosed patients seizure free, a significant number of patients have chronic intractable epilepsy causing disability with considerable socioeconomic implications. There is, therefore, a need fo...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199411010-00005

    authors: Patsalos PN,Sander JW

    更新日期:1994-07-01 00:00:00

  • Comparative safety and efficacy of proton pump inhibitors in paediatric gastroesophageal reflux disease.

    abstract::Gastroesophageal reflux is one of the most common reasons for referrals to paediatricians or paediatric gastroenterologists. Gastric acid-buffering agents, mucosal surface barriers and gastric anti-secretory agents are the main groups of medications currently used for treating gastroesophageal reflux disease (GERD) in...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-014-0154-y

    authors: Kierkus J,Oracz G,Korczowski B,Szymanska E,Wiernicka A,Woynarowski M

    更新日期:2014-05-01 00:00:00

  • Acute fluoride toxicity. Pathophysiology and management.

    abstract::Acute intoxication with inorganic fluoride disrupts numerous physiological systems. As a potent acid it acts corrosively on the skin and mucous membranes, producing severe burns. As the most electronegative element it tightly binds many cations essential to homeostasis, producing, for example, profound hypocalcaemia a...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199005020-00001

    authors: McIvor ME

    更新日期:1990-03-01 00:00:00

  • In vitro models.

    abstract::The development of in vitro models is advancing rapidly, with the application of cell culture methods as an alternative to animals in toxicological screening; non-cellular systems are also being used. Any screening test, whether for detecting irritants, carcinogens or teratogens should be well validated against known ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199000051-00006

    authors: Anderson D

    更新日期:1990-01-01 00:00:00

  • Comment on: "All-Cause and Drug-Related Medical Events Associated with Overuse of Gabapentin and/or Opioid Medications: A Retrospective Cohort Analysis of a Commercially Insured US Population".

    abstract:: ...

    journal_title:Drug safety

    pub_type: 评论,信件

    doi:10.1007/s40264-018-0670-2

    authors: Kawada T

    更新日期:2018-06-01 00:00:00

  • Methods for retrospective detection of drug safety signals and adverse events in electronic general practice records.

    abstract:BACKGROUND:Examination of clinical data routinely recorded in general practice provides significant opportunities for identifying and quantifying medicine-related adverse events not captured by spontaneous adverse reaction reporting systems. Robust pharmacovigilance methods for detecting and monitoring adverse events d...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/BF03261970

    authors: Tomlin A,Reith D,Dovey S,Tilyard M

    更新日期:2012-09-01 00:00:00

  • Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.

    abstract::Blinatumomab is the first-and-only Food and Drug Administration (FDA)-approved cluster of differentiation (CD) 19-directed CD3 bispecific T-cell engager (BiTE®) immunotherapy. It is currently FDA approved for the treatment of adults and children with Philadelphia chromosome-positive (Ph+) and Philadelphia chromosome-n...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-018-0760-1

    authors: Stein A,Franklin JL,Chia VM,Arrindell D,Kormany W,Wright J,Parson M,Amouzadeh HR,Choudhry J,Joseph G

    更新日期:2019-05-01 00:00:00

  • Managing Risks with Immune Therapies in Multiple Sclerosis.

    abstract::Since the introduction of the interferons in the 1990s, a multitude of different immunomodulatory and immunosuppressant disease-modifying therapies for multiple sclerosis (MS) have been developed. They have all shown positive effects on clinical endpoints such as relapse rate and disease progression and are a heteroge...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-018-0782-8

    authors: Förster M,Küry P,Aktas O,Warnke C,Havla J,Hohlfeld R,Mares J,Hartung HP,Kremer D

    更新日期:2019-05-01 00:00:00

  • Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.

    abstract::Bisphosphonates are the primary pharmacological agents used for the management of osteoporosis and hypercalcaemia of malignant bone disease. The efficacy of these agents in these two conditions has been demonstrated in many well designed trials published over the past 2 decades. The variety of bisphosphonates currentl...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200629120-00005

    authors: Bobba RS,Beattie K,Parkinson B,Kumbhare D,Adachi JD

    更新日期:2006-01-01 00:00:00

  • Enabling Data-Driven Clinical Quality Assurance: Predicting Adverse Event Reporting in Clinical Trials Using Machine Learning.

    abstract:INTRODUCTION:Adverse event (AE) under-reporting has been a recurrent issue raised during health authorities Good Clinical Practices (GCP) inspections and audits. Moreover, safety under-reporting poses a risk to patient safety and data integrity. The current clinical Quality Assurance (QA) practices used to detect AE un...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-019-00831-4

    authors: Ménard T,Barmaz Y,Koneswarakantha B,Bowling R,Popko L

    更新日期:2019-09-01 00:00:00

  • Correction to: vigiGrade: A Tool to Identify Well-Documented Individual Case Reports and Highlight Systematic Data Quality Issues.

    abstract::The article vigiGrade: A Tool to Identify Well-Documented Individual Case Reports and Highlight Systematic Data Quality Issues, written by Tomas Bergvall. G. Niklas Norén. Marie Lindquist, was originally published Online First without open access. ...

    journal_title:Drug safety

    pub_type: 已发布勘误

    doi:10.1007/s40264-019-00803-8

    authors: Bergvall T,Norén GN,Lindquist M

    更新日期:2019-06-01 00:00:00